Aging as a Risk Factor and Target for Prevention of Liver Cancer
Aging as a Risk Factor and Target for Prevention of Liver Cancer
批准号:
10698098
负责人:
PETER D. ADAMS
金额:
$258.54万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-15 至 2026-08-31
关键词:
AgeAge YearsAgingBenignBile AcidsBiochemical PathwayBody fatCellsCholesterolChromatinChronicCirrhosisCoupledDNA Sequence AlterationDependenceDiseaseDisease ManagementDisease OutcomeEarly DiagnosisEpigenetic ProcessEquilibriumEventFatty LiverFibrosisGeroscienceHomeostasisHypertensionImmuneImmunomodulatorsIncidenceInflammationInflammatoryInsulin ResistanceInterferon ActivationInterferonsInterventionKnowledgeLinkLiverLiver diseasesMalignant NeoplasmsMalignant neoplasm of liverMetabolic syndromeMetabolismMitochondriaMolecularMolecular ProfilingNatural ImmunityNeoplastic liverNormal tissue morphologyOrganismPathogenicityPredispositionPrevention strategyPrimary carcinoma of the liver cellsRiskRisk AssessmentRisk FactorsRoleSeveritiesSignal TransductionSirolimusSystemTestingTissuesadaptive immunityage relatedagedassessment applicationchronic liver diseasecombatepigenomeimmune functionimprovedindexingliver cancer preventionmetabolomeneoplasticnon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovel therapeuticspermissivenesspreventpreventive interventionprognosticationsenescencetranscriptometumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY – OVERALL
The incidences of liver cancer (primarily hepatocellular carcinoma (HCC)) are increasing and disease outcome
is poor. Consequently, there is an urgent need for new therapies and better preventive strategies. Age is a major
risk factor for HCC. In line with the geroscience hypothesis, we hypothesize that aging drives a dysfunctional
mitochondrial, epigenetic and metabolic network that promotes and exacerbates age-associated dysregulation
of immune function and inflammation in liver. Loss of homeostasis across multiple systems is permissive for
neoplastic liver disease. We further hypothesize that dysregulated chronic interferon signaling is central to this
pathogenic network. We will dissect this network and test the consequence of chronic interferon signaling, to
understand why the incidence of liver cancer increases with age. We will also investigate approaches that target
this network for their ability to prevent and combat liver cancer. Our overall specific objectives are:
Objective 1. Investigate age-associated changes to mitochondria, chromatin, metabolism (specifically, bile acids)
and innate and adaptive immunity, their causal role in HCC and underlying mechanisms.
Objective 2. Investigate how interactions between these different systems and age-dependent dysregulation of
these interactions contributes to HCC.
Objective 3. Test the hypothesis that at least some of these age-associated alterations and consequent
predisposition to HCC are dependent on chronic interferon signaling in aged tissue.
Objective 4. Investigate approaches that target age dysregulation, for example suppressors of chronic interferon
activation, mitohormetic interventions, rapamycin, senolytics, bile acid modulators and immune-modulators, for
their ability to suppress the onset of liver cancer and better counter established cancer.
Since age is the biggest single risk factor for HCC, it follows that a molecular understanding of the age-
dependence of HCC can lead to improved disease management through risk assessment, early detection,
prognostication and therapy. Moreover, an understanding of how HCC develops during aging can also lead to
preventative interventions. This PPG will define critical molecular mechanisms underpinning age-dependence of
HCC. We will also promote approaches for improved risk assessment through application, testing and refinement
of a transcriptome-based “tumorigenic index” to quantitate the risk of HCC. Finally, based on our discoveries,
we will test a panel of candidate interventions for those that can prevent and combat HCC.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Spatial mapping senescent cells across the mouse lifespan by multiplex transcriptomics and epigenomics
-
批准号:10553044
-
项目类别:
-
资助金额:$256.68万
-
财政年份:2022
-
负责人:PETER D. ADAMS
-
依托单位:
Bioanalysis Core
-
批准号:10553046
-
项目类别:
-
资助金额:$186.35万
-
财政年份:2022
-
负责人:PETER D. ADAMS
-
依托单位:
Admin Core
-
批准号:10673204
-
项目类别:
-
资助金额:$35.16万
-
财政年份:2022
-
负责人:PETER D. ADAMS
-
依托单位:
Spatial mapping senescent cells across the mouse lifespan by multiplex transcriptomics and epigenomics
-
批准号:10673203
-
项目类别:
-
资助金额:$269.03万
-
财政年份:2022
-
负责人:PETER D. ADAMS
-
依托单位:
Admin Core
-
批准号:10553045
-
项目类别:
-
资助金额:$12.6万
-
财政年份:2022
-
负责人:PETER D. ADAMS
-
依托单位:
Bioanalysis Core
-
批准号:10673207
-
项目类别:
-
资助金额:$183.85万
-
财政年份:2022
-
负责人:PETER D. ADAMS
-
依托单位:
Mechanisms that couple irregular development of fetal melanoblasts to premature exhaustion of adult melanocyte stem cells
-
批准号:10461955
-
项目类别:
-
资助金额:$59.9万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Digital Spatial Profiler Analysis Instrument
-
批准号:10175562
-
项目类别:
-
资助金额:$30.25万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Cytoplasmic chromatin fragments in cell senescence - novel mechanisms and interventions
-
批准号:10185176
-
项目类别:
-
资助金额:$62.86万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Mechanisms that couple irregular development of fetal melanoblasts to premature exhaustion of adult melanocyte stem cells
-
批准号:10620343
-
项目类别:
-
资助金额:$60.72万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Cytoplasmic chromatin fragments in cell senescence - novel mechanisms and interventions
-
批准号:10400070
-
项目类别:
-
资助金额:$39.34万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Aging as a Risk Factor and Target for Prevention of Liver Cancer
-
批准号:10488671
-
项目类别:
-
资助金额:$259.58万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Cytoplasmic chromatin fragments in cell senescence - novel mechanisms and interventions
-
批准号:10604324
-
项目类别:
-
资助金额:$39.34万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Project 2: Cytoplasmic chromatin fragments (CCF) as a driver of liver cancer and target for intervention during aging
-
批准号:10270687
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Mechanisms that couple irregular development of fetal melanoblasts to premature exhaustion of adult melanocyte stem cells
-
批准号:10306200
-
项目类别:
-
资助金额:$60.05万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Core A: Administrative
-
批准号:10698099
-
项目类别:
-
资助金额:$25.14万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Aging as a Risk Factor and Target for Prevention of Liver Cancer
-
批准号:10270682
-
项目类别:
-
资助金额:$253.14万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Project 2: Cytoplasmic chromatin fragments (CCF) as a driver of liver cancer and target for intervention during aging
-
批准号:10698106
-
项目类别:
-
资助金额:$41.16万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Core A: Administrative
-
批准号:10270683
-
项目类别:
-
资助金额:$41.04万
-
财政年份:2021
-
负责人:PETER D. ADAMS
-
依托单位:
Defining chromostasis - a candidate regulator of healthy aging and longevity
-
批准号:10655470
-
项目类别:
-
资助金额:$80.97万
-
财政年份:2020
-
负责人:PETER D. ADAMS
-
依托单位:
海外基金